Compare Harmony Gold Mining Co. (HMY) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Harmony Gold Mining Co. trades at $16.65 (market cap $10.37B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Harmony Gold Mining Co. is far larger — about 10.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Harmony Gold Mining Co. pays a 4.67% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Harmony Gold Mining Co. for 45 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HMY | MRVI | |
|---|---|---|
Market Cap | $10.37B | $972.90M |
Volume | 2,951,252 | 4,325,710 |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $9.00 |
52-Week Low | $13.32 | $2.83 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $10.42B | $1.08B |
Dividend Yield | 4.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HMY trades at $16.29, down 2.34% today, amid bearish technical signals but strong fundamentals. The stock shows robust revenue growth from $42.6B in 2022 to $73.9B in 2025, with net income surging to $14.4B. Valuation ratios remain attractive with P/E of 5.96 and EV/EBITDA of 3.64. Recent earnings showed mixed results with two beats and two misses in the last four quarters.
The outlook is cautiously optimistic given strong profitability metrics (ROE 46.23%, net margin 29.57%) and copper expansion plans, though technical weakness and analyst skepticism (70% hold rating) suggest near-term volatility. Key risks include gold price dependency and execution challenges in diversification efforts.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
